1 |
Canney M, O′Hara PV, McEvoy CM, et al. Spatial and temporal clustering of anti-glomerular basement membrane disease [J]. Clin J Am Soc Nephrol, 2016, 11(8): 1392-1399.
|
2 |
Ooi JD, Petersen J, Tan YH, et al. Dominant protection from HLA linked autoimmunity by antigen-specific regulatory T cells [J]. Nature, 2017, 545(7653): 243-247.
|
3 |
Henderson Scott R, Salama Alan D. Diagnostic and management challenges in Goodpasture′s (anti-glomerular basement membrane) disease [J]. Nephrol Dial Transplant, 2018, 33(2): 196-202.
|
4 |
Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture′s disease (anti-GBM) [J]. J Autoimmunity, 2014, 48-49: 108-112.
|
5 |
李丽娟,李晓梅,曾彩虹. 114例抗肾小球基底膜抗体阳性结果分析 [J]. 检验医学与临床, 2018, 15(21): 3186-3190.
|
6 |
McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease [J]. CJASN, 2017, 12(7): 1162-1172.
|
7 |
朱厚玲,邱红渝. 抗基底膜抗体肾炎伴抗中性粒细胞胞浆抗体阳性的新月体肾小球肾炎一例 [J]. 华西医学, 2017, 32(5): 795-796.
|
8 |
Serra G, Brun AL, Toledano D, et al. Thoracic involvement in systemic primary vasculitis: radiological patterns and follow-up [J]. JBR-BTR, 2014, 97(2): 57-68.
|
9 |
Ohlsson S, Herlitz H, Lundberg S, et al. Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and falsenegative immunoassay test results in anti-glomerular basement membrane disease [J]. Am J Kidney Dis, 2014, 63: 289-293.
|
10 |
Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies [J]. Nephrol Dial Transplant, 2019, 34: 1826-1832.
|
11 |
Nasr SH, Collins AB, Alexande MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis [J]. Kidney Int, 2016, 89(4): 897-908.
|
12 |
Marques C, Carvelli J, Biard L, et al. Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients [J]. Front Immunol, 2019, 10: 1665.
|
13 |
Alchi B, Griffiths M, Sivalingam M, et al. Predictors of renal and patient outcomes in anti-GBM disease: Clinicopathologic analysis of a two-centre cohort [J]. Nephrol Dial Transplant, 2015, 30: 814-821.
|
14 |
McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients [J]. Kidney Int, 2017, 92(3): 693-702.
|
15 |
Huart A, Josse AG, Chauveau D, et al. Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis [J]. J Autoimmun, 2016, 73: 24-29.
|
16 |
Van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis [J]. Clin J Am Soc Nephrol, 2018, 13: 63-72.
|
17 |
Chen S, Tang Z, Xiang HY, et al. Etiology and outcome of crescentic glomerulonephritis from a single center in China: A 10-year review [J]. Am J Kidney Dis, 2016, 67(3): 376-383.
|
18 |
Liang D, Liang S, Xu F, et al. Clinicopathological features and outcome of antibody-negative anti-glomerular basement membrane disease [J]. J Clin Pathol, 2019, 72(1): 31-37.
|
19 |
Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis [J]. Kidney Int, 2016, 89: 897-908.
|
20 |
Nagano C, Goto Y, Kasahara K, et al. Case report: anti-glomerular basement membrane antibody disease with normal renal function [J]. BMC Nephrol, 2015, 16: 185.
|
21 |
Troxell ML, Houghton DC. Atypical anti-glomerular basement membrane disease [J]. ClinKidney J, 2016, 9, 211-221.
|
22 |
贾晓玉,刘丽萍,崔昭,等. 血浆置换治疗清除抗肾小球基底膜抗体的效率及其与肾脏预后的关系 [J].中国血液净化, 2018, 17(10): 672-676.
|
23 |
Biesenbach P, Kain R, Derfler K, et al. Long-term outcome of antiglomerular basement membrane antibody disease treated with immunoadsorption [J]. PLoS One, 2014, 9:e103568.
|
24 |
Winstedt L, Jarnum S, Nordahl EA, et al. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS-a novel therapeutic opportunity [J]. PLoS One, 2015, 10: e0132011.
|
25 |
TouzotM, Poisson J, Faguer S, et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients [J]. J Autoimmun, 2015, 60: 74-79.
|
26 |
Heitz M, Carron PL, Clavarino G, et al. Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease [J]. BMC Nephrology, 2018, 19(1): 241.
|
27 |
Xu DC, Wu JX, Mei CL, et al. Novel therapy for anti-glomerular basement membrane basement membrane disease with Ig A nephropathy: a case report [J]. Exp Ther Med, 2016, 11(5): 1889-1892.
|
28 |
Ma KW, Mcadoo SP, Tam FWK. Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond [J]. Nephrol Dial Transplant, 2017, 32(suppl 1): 129-138.
|
29 |
祁青,何世君,唐炜,等. 雷公藤内酯醇LLDT-8在抗GBM抗体诱导小鼠肾炎中的疗效作用及对Fc受体介导淋巴细胞活化的调控机制 [J]. 中国药理学与毒理学杂志. 2016, (10): 1033-1034.
|